-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

634.O3.6 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Risk Stratification and Prognostication Clinically Relevant Abstract

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Adults, MPN, Workforce, Health Outcomes Research, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Chronic Myeloid Malignancies, Diseases, Real World Evidence, Myeloid Malignancies, Young Adults, Study Population
Saturday, December 11, 2021: 2:00 PM-3:30 PM
B405-B407, Level 4, Building B (Georgia World Congress Center)
Moderators:
Andrew T. Kuykendall, MD, H. Lee Moffitt Cancer Center and Research Institute and Kristen M. Pettit, The University of Michigan
Disclosures:
Kuykendall: Abbvie: Honoraria; BluePrint Medicines: Honoraria, Research Funding, Speakers Bureau; Celgene/BMS: Honoraria, Research Funding, Speakers Bureau; CTI Biopharma: Honoraria; Incyte: Consultancy; Novartis: Honoraria, Speakers Bureau; PharmaEssentia: Honoraria; Prelude: Research Funding; Protagonist: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding.
2:00 PM

Khalid Abu-Zeinah1*, Khalil Saadeh, BA1*, Richard T. Silver, MD2, Joseph Scandura, MD, PhD2 and Ghaith Abu-Zeinah, MD2

1University of Cambridge, Cambridge, United Kingdom
2Richard T. Silver, M.D. Myeloproliferative Neoplasms (MPN) Center, Weill Cornell Medicine, New York, NY

2:15 PM

Tiziano Barbui1*, Arianna Ghirardi, BSc2*, Alessandra Carobbio, BSc2*, Arianna Masciulli, PhD2*, Greta Carioli, PhD2*, Alessandro Rambaldi, MD3,4, Maria Chiara Finazzi, MD3,4*, Marta Bellini, MD3*, Elisa Rumi, MD5,6*, Daniele Vanni, MD6*, Oscar Borsani, MD6*, Francesco Passamonti, MD7,8*, Barbara Mora, MD8,9*, Marco Brociner, MD7*, Alessandro Vannucchi, MD10,11, Paola Guglielmelli, MD, PhD10,11, Chiara Paoli, PhD10,11*, Alberto Alvarez-Larran12*, Ana Triguero13*, Marta Garrote, MD14*, Helna Pettersson, MD15* and Björn Andréasson, MD, PhD15*

1FROM Research Foundation ASST Papa Giovanni XXIII Bergamo, Bergamo, Italy
2FROM Research Foundation Ospedale di Bergamo, Bergamo, Italy
3Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
4University of Milan, Milan, Italy
5Department of Molecular Medicine, University of Pavia, Pavia, Italy
6Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
7Hematology, ASST Sette Laghi, Varese, Italy
8University of Insubria, Varese, Italy
9Hematology, University Hospital "Ospedale di Circolo e Fondazione Macchi" - ASST Sette Laghi, University of Insubria, Varese, Italy
10University of Florence, Florence, Italy
11CRIMM, Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy
12Hematology Department, Hematology Department, Hospital ClíNic, Barcelona, Spain
13Hospital Clinic of Barcelona, Hematology Department, Barcelona, Spain
14Hematopathology Unit, Pathology Department, Hospital Clinic, Barcelona, Spain
15Division of Hematology, NU Hospital Group, Uddevalla, Sweden

2:30 PM

Giuseppe Gaetano Loscocco, MD1*, Paola Guglielmelli, MD, PhD1, Carmela Mannarelli, PhD1*, Elena Rossi, MD, PhD2*, Francesco Mannelli, MD1*, Francesco Ramundo2*, Giacomo Coltro, MD3*, Silvia Betti, MD, PhD2*, Chiara Maccari1*, Sara Ceglie, MD2*, Chiara Paoli, PhD1*, Tiziano Barbui, MD4*, Ayalew Tefferi, MD5, Valerio De Stefano6* and Alessandro Vannucchi1

1University of Florence, AOU Careggi, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Italy, Florence, Italy
2Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Roma, Italy
3University of Florence, AOU Careggi, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Italy, Florence, Italy, Florence, Italy
4FROM Research Foundation Bergamo, Bergamo, Italy
5Division of Hematology, Mayo Clinic, Rochester, MN
6Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy

2:45 PM

Ayalew Tefferi, MD1, Giuseppe Gaetano Loscocco, MD2*, Faiqa Farrukh, MBBS3*, Natasha Szuber, MD, MSc4, Francesco Mannelli, MD5*, Animesh D. Pardanani, MBBS, PhD1, Curtis A. Hanson, MD6, Valerio De Stefano7*, Tiziano Barbui, MD8*, Paola Guglielmelli, MD, PhD9, Naseema Gangat, MBBS1 and Alessandro Vannucchi10

1Division of Hematology, Mayo Clinic, Rochester, MN
2CRIMM,Center for Research and Innovation of Myeloproliferative Neoplasms, AOU Careggi, Florence, Italy
3Mayo Clinic, Rochester
4Hôpital Maisonneuve-Rosemont, Department of Hematology, Montreal, QC, Canada
5University of Florence, AOU Careggi, CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, Italy, Florence, Italy
6Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
7Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico A Gemelli, IRCCS, Rome, Italy
8Research Foundation, Hospital Papa Giovanni XXIII, Bergamo, Italy,, BERGAMO, Italy
9CRIMM, Center for Research and Innovation of Myeloproliferative Neoplasms, University of Florence, Florence, Italy
10University of Florence, Firenze, Italy

3:00 PM

Aaron T. Gerds, MD, MS1, Ruben A. Mesa, MD, FACP2, John M. Burke, MD3, Michael R. Grunwald, MD4, Brady Lee Stein, MD5, Robyn Scherber, MD, MPH6, Jingbo Yu, MD, PhD6, J.E. Hamer-Maansson, MSPH6* and Stephen Oh, MD, PhD7*

1Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
2UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX
3Rocky Mountain Cancer Centers, Aurora, CO
4Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC
5Northwestern University Feinberg School, Chicago, IL
6Incyte Corporation, Wilmington, DE
7Washington University School of Medicine, St. Louis, MO

3:15 PM

Douglas Tremblay, MD1, Andrew Srisuwananukorn, MD1, Lukas Ronner, MD2, Nikolai Podoltsev, MD, PhD3, Jason Gotlib, MD, MS4, Mark L. Heaney, MD5, Andrew T. Kuykendall, MD6, Casey L. O'Connell, MD7, Jamile M. Shammo, MD8, Angela Fleischman, MD, PhD9, Ruben A. Mesa, MD, FACP10, Abdulraheem Yacoub, MD11, Ronald Hoffman, MD12, Erin Moshier, MS13*, Nicole Zubizarreta13* and John Mascarenhas, MD1

1Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY
2Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA
3Yale University School of Medicine, New Haven, CT
4Stanford Cancer Center, Stanford, CA
5Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
6Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
7Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, CA
8Division of Hematology/Oncology, Rush Univ. Med. Ctr., Chicago, IL
9University of California, Irvine, Irvine, CA
10Mays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, TX
11The University of Kansas Cancer Center, Leawood, KS
12Tisch Cancer Institute, Icahn School of Medicine At Mount Sinai Medical Center, New York, NY
13Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

*signifies non-member of ASH